A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment

Approximately 20% of HER2 positive breast cancer develops disease recurrence after adjuvant trastuzumab treatment. This study aimed to develop a molecular prognostic model that can reliably stratify patients by risk of developing disease recurrence. Using miRNA microarrays, nine miRNAs that differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, F., Yuan, P., Zhao, Z. T., Yang, Z., Wang, T., Zhao, J. D., Luo, Y., Ma, F., Wang, J. Y., Fan, Y., Cai, R. G., Zhang, P., Li, Q., Song, Y. M., Xu, B. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030658/
https://www.ncbi.nlm.nih.gov/pubmed/27650797
http://dx.doi.org/10.1038/srep33825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030658/
https://www.ncbi.nlm.nih.gov/pubmed/27650797
http://dx.doi.org/10.1038/srep33825

Ejemplares similares